Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Merlin Biomed

Investor type Hedge Fund
Founders Stuart T. Weisbrod

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 18
Average round size
info
The average size of a deal this fund participated in
$30M
Portfolio companies 16
Rounds per year 0.75
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 11
Key employees Soon
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Therapeutics
  • Medical
Summary

Merlin Biomed appeared to be the Corporate Investor, which was created in 1998. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the New York.

Among the most popular fund investment industries, there are Health Care, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight ARIAD Pharmaceuticals, FibroGen, Calypso Medical. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The average startup value when the investment from Merlin Biomed is 10-50 millions dollars. Opposing the other organizations, this Merlin Biomed works on 36 percentage points more the average amount of lead investments. The increased amount of exits for fund were in 2014. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2003. The fund is constantly included in less than 2 deals per year.

The fund was created by Stuart T. Weisbrod.

The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the Merlin Biomed, startups are often financed by Bay City Capital, Versant Ventures, Venrock. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, VantagePoint Capital Partners, OrbiMed. In the next rounds fund is usually obtained by OrbiMed, MPM Capital, Sanderling Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Merlin Biomed:
Typical Co-investors
Merlin Biomed is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Merlin Biomed:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
BDC Capital Canada, Montréal, Quebec
Blue Maple Beijing, Beijing, China
Church Street Trustees -
Cork Japan, Tokyo
Dayiwang Beijing, Beijing, China
Lakewood Capital -
Liberty Technologies, Inc. Liberty, Missouri, United States
LOGLY INVESTMENT Chiyoda, Japan
MAA Group Kuala Lumpur, Malaysia
Metavallon VC Athens, Attiki, Greece
Mosaic Asset Management Irving, Texas, United States
Nepenthe Capital -
Phoebus China, Minhang, Shanghai
Radian Capital New York, New York, United States
Sandoz Foundation -
Shenzhenshi Qianhai Zeqing Zichan Guanli Youxian Gongsi China, Guangdong, Tianjin
Spring Marketing Capital -
The Ledger Group Canada, Ontario, Toronto
The Sparkle Fund -
Winnipeg Capital Lima, Lima, Peru

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

CymaBay Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$8M05 Nov 2009 Hayward, California, United States

Gemin X Pharmaceuticals

Biotechnology
Pharmaceutical
Therapeutics
$38M03 Jul 2008 Montreal, Quebec, Canada

CymaBay Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$32M19 Apr 2007 Hayward, California, United States

Calypso Medical

Health Care
Medical
Medical Device
$42M08 Jan 2007 Seattle, Washington, United States

EUSA Pharma

Biotechnology
Health Care
Medical
Pharmaceutical
$18M07 Nov 2006 United Kingdom, England, United Kingdom

Biotechnology
Health Care
Medical
$40M07 Sep 2006 Massachusetts, United States

Genelabs Technologies

Biopharma
Biotechnology
Health Care
Therapeutics
$8M27 Jun 2006 Redwood City, California, United States

Affymax

Biopharma
Biotechnology
Health Care
$60M18 Jul 2005 Cupertino, California, United States

FibroGen

Biopharma
Biotechnology
Therapeutics
$100M17 Feb 2005 San Francisco, California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Merlin Biomed?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: